Therefore, this study aims to compare seven screening strategies (US, AFP, PIVKA-II, AFP+US, AFP+PIVKA-II, GAAD and GAAD+US) by developing a health economic model from the Chinese healthcare system perspective to identify the most cost-effective strategy for early detection of liver cancer in patients with CHB in China. This evidence concerns the gene AFP and liver cancer.